Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration

• Published in: Pregnancy hypertension Vol. 34; pp. 74 - 82
• Main Authors: Bhat, Adithya D, Keasler, Paige M, Kolluru, Lavanya, Dombrowski, Michael M, Palanisamy, Arvind, Singh, Preet Mohinder
• Format: Journal Article
• Language: English
• Published: Netherlands 01-12-2023
• Subjects: Antihypertensive Agents; Calcium Channel Blockers - therapeutic use; Female; Humans; Hydralazine - therapeutic use; Hypertension - drug therapy; Infant, Newborn; Ketanserin - therapeutic use; Methyldopa; Network Meta-Analysis; Nifedipine - therapeutic use; Pre-Eclampsia - drug therapy; Pregnancy; Randomized Controlled Trials as Topic; Hypertension; Antihypertensives; Network meta-analysis
• ISSN: 2210-7789; 2210-7797
• DOI: 10.1016/j.preghy.2023.10.005

Consensus on the relative efficacy of available antihypertensive agents used in pregnancy is lacking.
To compare treatment success with antihypertensives and categorize by route of administration.
MEDLINE, Embase, PubMed, Web of Science, Scopus, CINAHL, and clinicaltrials.gov were searched without date restriction.
Peer-reviewed randomized controlled trials (RCTs) comparing pharmacologic agents used to treat hypertension in parturients were included. Evaluated treatment groups included IV-labetalol (BBIV), IV-hydralazine (DIV), oral-nifedipine (CCBPO), sublingual nifedipine (CCBSL), IV-calcium channel blocker (nonspecific)(CCBIV), IV-nitroglycerine (NTG), epoprostenol infusion (PRO), IV-ketanserin (5HT2B), IV-diazoxide (BZO), oral-nifedipine + methyldopa (CCBAG), oral-methyl-dopa (AAG), and oral prazosin (ABPO).
Seventy-four studies (8324 patients) were eligible post PRISMA guidelines screening. Results were pooled using a Bayesian-approach for success of treatment (study defined target blood pressure), time to achieve target pressure, and neonatal intensive-care admissions.
Treatment success (primary outcome, 55 trials with 5518 patients) was analyzed. Surface under the cumulative ranking curve (SUCRA) was categorized for 13 drugs, CCBPO (0.84) followed by CCBSL (0.78) were most likely to be effective in achieving target blood pressure. After sub-grouping by presence/absence of preeclampsia, CCB-PO ranked highest for both [(0.82) vs. (0.77), respectively]. Serotonin antagonists (0.99) and nitroglycerin (0.88) ranked highest for time to target pressure. NICU admissions were lowest for alpha-2 agonists (0.89), followed by BB PO (0.82) and hydralazine IV (0.49).
Oral calcium-channel blockers ranked highest for treatment success. Ketanserin achieved target blood pressure fastest, warranting additional research. The results should be interpreted with caution as SUCRA values may not indicate whether the differences between interventions have clinically meaningful effect sizes.